How would you treat a potentially resectable stage III lung adenocarcinoma with an EGFR mutation?   

Do you consider any neoadjuvant therapy or proceed to surgery followed by adjuvant chemotherapy and osimertinib? Does the type of mutation (ex a rare exon 19 mutation) change affect your decision?

Answer from: Medical Oncologist at Academic Institution